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ABSTRACT
Nuclear factor (NF)-iB is a master regulator of
pro-inflammatory genes and is upregulated in
human immunodeficiency virus 1 (HIV-1) infection.
Mechanisms underlying the NF-iB deregulation by
HIV-1 are relevant for immune dysfunction in AIDS.
We report that in single round HIV-1 infection,
or single-pulse PMA stimulation, the HIV-1 Tat
transactivator activated NF-iB by hijacking the
inhibitor IiB-a and by preventing the repressor
binding to the NF-iB complex. Moreover, Tat
associated with the p65 subunit of NF-iB and
increased the p65 DNA-binding affinity and tran-
scriptional activity. The arginine- and cysteine-rich
domains of Tat were required for IiB-a and p65 as-
sociation, respectively, and for sustaining the NF-iB
activity. Among an array of NF-iB-responsive
genes, Tat mostly activated the MIP-1a expression
in a p65-dependent manner, and bound to the
MIP-1a NF-iB enhancer thus promoting the recruit-
ment of p65 with displacement of IiB-a; similar
findings were obtained for the NF-iB-responsive
genes CSF3, LTA, NFKBIA and TLR2. Our results
support a novel mechanism of NF-iB activation via
physical interaction of Tat with IiB-a and p65, and
may contribute to further insights into the deregula-
tion of the inflammatory response by HIV-1.
INTRODUCTION
Nuclear factor (NF)-kB transcription factors regulate the
transcription of genes that are involved in the immune and
inﬂammatory response (1). The NF-kB family includes
RelA/p65, c-Rel, RelB, p50 and p52 that share a highly
conserved 300-amino acid Rel homology domain (RHD)
for homo- or hetero-dimerization and DNA-binding. The
transcriptional activity of the NF-kB complex depends on
dimer composition since C-terminal unrelated transcrip-
tional activation domains are present exclusively in p65,
RelB and c-Rel (2).
Inhibitors of NF-kB( I kB) associate with the NF-kB
complex and interfere with its binding to DNA (3). In the
canonical pathway of NF-kB activation, the activated IkB
kinase (IKK) phosphorylates IkB at speciﬁc serine residues
that target the protein to ubiquitination and proteasomal
degradation, which releases the functional NF-kB complex
in the nucleus. IkB-a, the most abundant inhibitor of
NF-kB (4), is phosphorylated by IKK at Ser32 and Ser36
(5), and subsequently ubiquitylated at Lys21 and Lys22 to
bedegradedbythe26Sproteasome(6).TheNF-kBactivity
is enhanced by phosphorylation of p65 at Ser276 by PKA
and MSK1 (7,8), Ser311 by PKCz (9) and Ser536 by IKKa
(10,11). Acetylation of p65 at Lys218 and Lys221 increases
the DNA binding and impairs the association with IkB-a,
and acetylation at Lys310 enhances the p65 transcriptional
activity (12,13). Post-activation turn off of NF-kBi s
regulated by negative feedback loop through inhibitors
under the transcriptional control of NF-kB, such
as IkB-a and ubiquitin-editing protein A20 (14–20).
Deacetylation of p65 by histone deacetylase-3 or SIRT1,
or acetylation of p65 at Lys122 and Lys123 down-regulate
the NF-kB activity (12,21,22).
Persistent activation of NF-kB occurs in human immu-
nodeﬁciency virus-1 (HIV-1)-infected monocytes, macro-
phages and microglia, and enhances the expression of
NF-kB-responsive genes, including pro-inﬂammatory
cytokines, cell adhesion molecules and chemokines
(23–25). Chronic inﬂammation is a major cause of
immune and neuron dysfunction in AIDS (26,27).
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munodeﬁciency virus, such as African green monkeys
and sooty mangabey, lack aberrant immune activation
and do not develop AIDS despite high virus replication
(28,29). Thus, understanding the mechanisms of NF-kB
deregulation by HIV-1 may provide further insights into
AIDS pathogenesis.
In HIV-1 entry, the binding of the gp120 viral envelope
to CD4 induces the NF-kB activity by activation of IKK
(30) and procaspase 8 (31). Following viral integration,
the early encoded HIV-1 Tat protein interacts with the
HIV-1 RNA and host cell factors to sustain the viral rep-
lication. Tat binds to RNA stem-loop structures generated
by the 50 end of target transcripts, including the HIV-1
transactivation-responsive element (TAR) (32), tumor
necrosis factor b (TNFb) (33) and interleukin-6 (IL-6)
(34) to activate gene transcription. Indeed, Tat promotes
the transcriptional initiation and elongation by interacting
with transacting factors and cofactors, such as Sp1 (35),
TFIID (36), E2F-4 (37), C/EBPb (38), cyclin T1/CDK9
(39,40) and the histone acetyltransferases p300/CBP and
P/CAF (41–43). When released from HIV-1-infected cells,
Tat deregulates the cell signaling by binding to cell recep-
tors, such as integrins (44), Flk1/KDR receptor (45) and
chemokine receptors (46).
We ﬁrst reported that NF-kB was constitutively active
in Jurkat cells that stably expressed the Tat gene (47).
Following gene transfection or protein transduction, Tat
induced the IKK activity and proteasomal degradation of
IkB-a (48), and increased the p65 transcriptional activity
by inhibiting the SIRT-1-mediated deacetylation of p65
Lys310 (49). These ﬁndings suggested that Tat modulates
crucial enzymes involved in NF-kB signaling; however, it
was unclear how Tat could subvert the negative feedback
of NF-kB, which is mainly dependent on de novo synthesis
of IkB-a (15,17). We previously found that IkB-a binds
to Tat and promotes the nuclear export of the viral
transactivator (50,51). In this study, we report that Tat
counteracts the post-activation turn off of NF-kB
through direct interaction with IkB-a and p65, which
enhances the DNA binding and transcriptional activity
of the NF-kB complex. The new mechanism of NF-kB
deregulation here described may provide further insights
into the chronic immune activation of HIV-1 infection.
MATERIALS AND METHODS
Plasmids
The plasmids pcDNA-3xHA-IkB-a, p3xFLAG-CMV-
Tat, p3xFLAG-CMV-Tat C(22,25,27)A, p3xFLAG-
CMV-Tat R(49,52,53,55,56,57)A, pGEX-2T-Tat,
pGEX-2T-Tat C(22,25,27)A and pGEX-2T-Tat
R(49,52,53,55,56,57)A were previously described (50).
The plasmids pNL4-3.Luc.R-E- and pHXB2-env were
obtained from the AIDS Research & Reference Reagent
Program, Division of AIDS, NIAID, NIH, USA; pkBluc
and pSV-b-Gal were purchased from Promega (Madison,
WI, USA). The plasmids pRc/CMV-3xHA-p65,
pRc/CMV-3xHA-p65C(1–318), pRc/CMV-3xHA-
p65N(122–551), p3xFLAG-CMV-Tat T,N(23,24)A,
p3xFLAG-CMV-Tat K(50,51)A, pGEX-2T-Tat
T,N(23,24)A, pGEX-2T-Tat K(50,51)A and pNL4-
3.FLAG-Tat.R-E- were generated as described in
Supplementary Data.
Cells, transfection, treatments and luciferase assay
HeLa, p50
 / p65
 /  mouse embryonic ﬁbroblasts
(MEFs) (52) and 293T cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium; Jurkat, U937 cells and human
peripheral blood mononuclear cells (PBMCs) were
cultured in RPMI 1640. PBMCs were isolated as previ-
ously described (53). Media were supplemented with 10%
heat-inactivated fetal calf serum and 2mM L-glutamine
(Lonza Cologne AG, Germany). HeLa, p50
 / p65
 / 
MEFs and 293T were transfected with DNA by using
FuGENE HD (Roche Diagnostic GmbH, Mannheim,
Germany), according to the manufacturer’s protocol;
total DNA amounts were equalized by transfection of
pRc/CMV empty vector (Invitrogen, Carlsbad, CA,
USA). For pulse-stimulation, HeLa cells were treated
with phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich, St Louis, MO, USA) (20ng/ml) for 5min, or
tumor necrosis factor-a (TNF-a; Sigma-Aldrich) (20ng/
ml) for 30min, washed twice in complete culture medium
and then returned to culture. For luciferase assays,
pSV-b-Gal was co-transfected with pkBluc to monitor the
transfection efﬁciency. Forty-eight-hour post-transfection,
cells were lysed in lysis buffer of Dual Light Luciferase
System (Tropix, Bedford, MA, USA) and the luciferase
and b-galactosidase activities were evaluated by using
Dual Light Luciferase System (Tropix) in a
bioluminometer (Turner Biosystem, Sunnyvale, CA,
USA). The ratio of ﬁreﬂy luciferase activity to
b-galactosidase activity was expressed as relative light
units.
RNA interference
Jurkat or U937 cells were transfected by electroporation
using a Bio-Rad apparatus (Bio-Rad Laboratories,
Hercules, CA, USA). Brieﬂy, aliquots (5 10
6 cells) were
suspended in 0.3ml of RPMI 1640 supplemented
with 20% fetal calf serum and subjected to a double elec-
trical pulse (0.22V, 960mF) in the presence of annealed
siRNA (200pmol); electroporated cells were washed and
cultured in complete medium. RNA interference was per-
formed with: siRNA Tat sense, CUGCUUGUACCAAU
UGCUAUU and siRNA Tat antisense, UAGCAAUUG
GUACAAGCAGUU; siRNA control sense, CUGCUUG
UCACA AUUGCUAUU and siRNA control antisense,
UAGCAAUUGUGACAAGCAGUU. RNA interference
of p65 and IkB-a was performed with SMART
pool siRNA p65 and IkB-a (Dharmacon, Chicago,
IL, USA).
Pseudotyped virions and single round infection
293T cells (1 10
7) were transfected with pNL4-
3.Luc.R-E- or pNL4-3.FLAG-Tat.R-E- (10mg) together
with pHXB2 Env (10mg), and 48-h post-transfection cell
supernatant was collected. Enzyme-linked immunosorbent
assay (ELISA) using anti-p24 antibody measured virion
Nucleic Acids Research,2012, Vol.40, No. 8 3549concentration. PBMCs, Jurkat or U937 cells (5 10
7)
were infected with HXB2 Env-pseudotyped virions
(500ng of p24) by spinoculation, as previously
described (50).
Cell extracts, western blotting, IKK activity and NF-iB
DNA binding
Total, nuclear and cytosolic extracts were performed as
previously described (54); details are reported in
Supplementary Data. Western blotting analysis was per-
formed by resuspending protein aliquots in loading buffer
(125mM Tris–HCl, pH 6.8, 5% SDS, 1% bromophenol
blue, 10% b-mercaptoethanol, 25% glycerol), resolved on
12% SDS–PAGE, transferred to polyvinylidene diﬂuoride
membrane (Millipore, Bedford, MA, USA) and incubated
with primary antibodies (1:1000) followed by incubation
with horseradish-peroxidase-linked mouse or rabbit IgG
(1:2000) (GE Healthcare Amersham, Little Chalfont,
Buckinghamshire, UK) in PBS containing 5% non-fat
dry milk (Bio-Rad Laboratories). Proteins were detected
by chemiluminescence using the ECL System (GE
Healthcare Amersham). Primary antibodies were
purchased from: Santa Cruz Biotechnology, Santa Cruz,
CA, USA (anti-HA F7, anti-IkB-a C15, anti-Histone H1,
anti-Hexokinase-II); Sigma-Aldrich (anti-FLAG M2,
anti-g-Tubulin); Upstate, Lake Placid, NY, USA (anti-
p65). Densitometry of single bands was analysed by
ImageJ software package (NIH, USA). IKK activity was
evaluated in cytosolic extracts using the HTScan IKK
kinase assay kit (Cell Signaling Technology, Danvers,
MA, USA). Binding of p65, p50 and FLAG-Tat to the
double-stranded NF-kB oligonucleotide was measured
using NF-kB Combo Transcription Factor Assay kit
(Cayman Chemical Company, Ann Arbor, MI, USA).
Electrophoretic Mobility Shift Assay (EMSA) was per-
formed as previously described (55); details are described
in Supplementary Data.
In vitro translation
HA-IkB-a, p65 and Tat were expressed under the T7
promoter and in vitro translated using the TnT quick
coupled transcription/translation system (Promega), as
previously reported (50). Details are described in
Supplementary Data.
Immunoprecipitation assay and GST-pull down
Immunoprecipitation, GST-pull down, and production of
GST proteins in Escherichia coli strain BL21 were per-
formed as previously reported (50). Details are described
in Supplementary Data.
Real-time PCR
Total RNA was extracted from cells by using the TRIzol
reagent (Invitrogen); RNA aliquots (200ng) were reverse
transcribed using Random Examers (Roche) and
Superscript III Reverse Transcriptase (Invitrogen), ac-
cording to the manufacturer’s protocol. Real-time PCR
was performed with the iQ Green Super mix (Bio-Rad
Laboratories) and carried out with the iCycler iQ
Real-Time detection system (Bio-Rad Laboratories)
under the following conditions: 95 C, 1min; (94 C, 10s;
60 C, 30s)  40. Primers for Tat and MIP-1  are listed in
Supplementary Data. Real-time PCR of CSF3, LTA,
NFKBIA, TLR2, GAPDH and ACTB was performed
using the RT
2 proﬁler PCR Array-Human NF-kB signal-
ing pathway (QIAGEN Sciences, MD, USA). Reactions
were carried out in triplicate, and gene expression levels
were calculated relative to GAPDH mRNA levels as en-
dogenous control. Relative expression was calculated as
2
(Ct gene under investigation Ct GAPDH).
Chromatin immunoprecipitation assay
Cells were ﬁxed by adding formaldehyde (Sigma-Aldrich)
at the ﬁnal concentration of 1%. After 10min, ice-cold
PBS plus 0.125M glycine was added, and plates were
transferred on ice, washed extensively with PBS, and
scraped. After centrifugation, cells were 10min lysed in
lysis buffer (5mM PIPES pH 8.0, 85mM KCl, 0.5%
NP-40) supplemented with 1  Complete Protease
Inhibitor (Roche Diagnostic GmbH). Nuclei were
pelletted (1000 g, 5min), and resuspended in sonication
buffer (50mM Tris–HCl pH 8.0, 1% SDS, 10mM
EDTA). Chromatin was sonicated using Bandelin
Sonoplus GM70 (Bandelin Electronic, Berlin, Germany),
centrifuged (14000 g, 15min), and supernatant was
10-fold diluted in dilution buffer (0.01% SDS, 16.7mM
Tris–HCl pH 8.0, 1.1% Triton X-100, 167mM NaCl,
1.2mM EDTA). Samples were pre-cleared by 3-h incuba-
tion with 20ml of protein G agarose beads followed by
incubation with antibodies against the analysed proteins.
Primary antibodies were: anti-p65 (sc-372), anti-IkBa
(sc-203) and rabbit IgG (sc-2027) from Santa Cruz
Biotechnology; anti-FLAG M2 from Sigma–Aldrich.
Immunoprecipitations were carried out at 4 C overnight
and immune complexes were collected with protein
G agarose beads, washed ﬁve times with low salt buffer
(20mM Tris–HCl pH 8.0, 0.1% SDS, 1% Triton X-100,
2mM EDTA, 150mM NaCl), four times with high salt
buffer (20mM Tris–HCl pH 8.0, 0.1% SDS, 1% Triton
X-100, 2mM EDTA, 500mM NaCl), once with TE buffer
(10mM Tris–HCl pH 8.0, 1mM EDTA), and extracted in
TE buffer containing 2% SDS. Protein–DNA cross-links
were reverted by heating at 65 C overnight. DNA was
further puriﬁed by QIAquick PCR puriﬁcation kit
(QIAGEN) and eluted in 50ml sterile distilled water.
Speciﬁc enrichment in NF-kB enhancer sequences was
measured by real-time PCR of chromatin immunopre-
cipitation (ChIP) eluates using SYBR GreenER Master
Mix (Invitrogen). Reactions were carried out with the
iCycler iQ Real-Time detection system (Bio-Rad
Laboratories) using the following conditions: 95 C,
1min; (94 C, 10s; 60 C, 30s)  40. Primers used for
MIP-1 , GAPDH and ACTB are listed in
Supplementary Data. Real-time PCR of CSF3, LTA,
NFKBIA and TLR2 were performed using the Custom
ChIP array (QIAGEN). For each sample, values were
normalized to input DNA and reported as % of input
over the rabbit IgG control.
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Statistical analysis was performed by two-tail unpaired
Student’s t-test. Data were reported as means±SE.
Differences between the means were considered as statis-
tically signiﬁcant at the 95% level (P<0.05).
RESULTS
Tat enhances the NF-iB activity by hijacking IiB-a and
inhibiting the post-activation turn off of NF-iB
We analysed the kinetic of NF-kB activation in single
round HIV-1 infection by modulating the expression
of Tat with RNA interference. Jurkat cells were trans-
fected with siRNA Tat, siRNA control, or left
untransfected, and 24h later cells were infected with
HXB2 Env-pseudotyped NL4-3.Luc.R
 E
  virions. By
cytoﬂuorimetric analysis,  40% of cells was siRNA-
transfected and HIV-1-infected at 12-h post-infection
(Supplementary Figure S1). The expression of Tat was
detected at 1-h post-infection and progressively increased
up to 12h in untransfected and siRNA control-transfected
cells, while it was barely detected in siRNA Tat-
transfected cells (Figure 1A). The LTR-dependent
luciferase expression was also progressively induced at 1-
to 12-h post-infection in untransfected and siRNA
control-transfected cells, while it was barely observed in
siRNA Tat-transfected cells, as expected for the
Tat-dependent transactivation of the HIV-1 LTR
(Figure 1A).
The progressive increase in NF-kB activity, as measured
by p65–p50 binding to an NF-kB consensus oligonucleo-
tide (Figure 1B) and nuclear p65 (Figure 1C, nucleus), was
observed at 1- to 3-h post-infection in both Tat-positive
(no siRNA or siRNA control) and Tat-negative (siRNA
Tat) cells; however, at 12-h post-infection, the p65 DNA
binding and nuclear p65 persisted elevated in presence of
Tat (no siRNA and siRNA control), while they dropped
in absence of Tat (siRNA Tat) (Figure 1B and C). IkB-a
was degraded in the cytosol within 3-h post-infection and
de novo synthesized at 6h with full replenishment at 12-h
post-infection in both Tat-positive and Tat-negative cells
(Figure 1C, cytosol). Consistently, the IKK activity was
induced at 1-h post-infection, and decreased at 3-h
post-infection independently of the presence of Tat
(Figure 1D). Similar kinetics of NF-kB activity, IKK ac-
tivation and IkB-a degradation/re-synthesis were observed
in single-round HIV-1 infection of PBMCs using a
cocktail of Azidothymidine (AZT) and Lamivudine
(3TC) as reverse transcriptase inhibitors (Supplementary
Figure S2). These results indicated that in single-round
HIV-1 infection the NF-kB activation initially correlated
with the IKK activation and IkB-a degradation independ-
ently of the presence of Tat, and it was kept elevated in
presence of Tat following the decay of the IKK activity
and new synthesis of IkB-a.
Next, we tested the single action of Tat on the kinetic of
NF-kB activity induced by PMA. To this end, HeLa cells
were transfected with p3x-FLAG-Tat, or empty vector,
stimulated with PMA for 5min, and extensively washed
to avoid the oscillatory kinetic of NF-kB activation
(17,18). In un-stimulated cells, the p65 DNA binding
(Figure 2A) and nuclear p65 (Figure 2B, nucleus) were
slightly enhanced by Tat, while the IkB-a content was
not signiﬁcantly affected (Figure 2B, cytosol). Transient
stimulation with PMA increased the NF-kB DNA binding
activity and nuclear p65 at 5min peaking at 60–120min
independently of the presence of Tat (Figure 2A and B);
however, while the p65 DNA binding and nuclear p65
persisted elevated at 240-min post-treatment in
Tat-positive cells, they dropped in Tat-negative cells
(Figure 2A and B). In addition, Tat bound to the
NF-kB oligonucleotide in un-stimulated cells and its
binding increased following PMA stimulation
(Figure 2A), suggesting that the viral protein was a com-
ponent of the NF-kB complex bound to DNA.
Degradation of IkB-a was progressively induced at
5–30min, followed by de novo synthesis at 60min with
full replenishment at 240min in both Tat-positive and
negative cells (Figure 2B, cytosol). Consistently, the
IKK activation started at 5min, and turned off at
30min independently of the presence of Tat (Figure 2C).
These results indicated that Tat enhanced the NF-kB
activity in un-stimulated and PMA-stimulated cells
without affecting the IKK activity and IkB-a content.
As we previously found that Tat binds to the sixth
ankyrin of IkB-a (50,51), we tested whether Tat counter-
acted the generation of the IkB-a/NF-kB complex. To this
end, the association of IkB-a with p65 was analysed in vivo
at 0 and 240min after short-pulse PMA, which corres-
ponded to the time of un-stimulated condition and
post-activation de novo synthesis of IkB-a, respectively.
Coimmunoprecipitation of IkB-a with p65 was detected
at 0- and 240-min post-treatment in Tat-negative cells
(Figure 2D, lanes 1 and 3), and was halved in
Tat-positive cells, where Tat coimmunoprecipitated with
IkB-a (Figure 2D, lanes 2 and 4), indicating that Tat
competed the IkB-a binding to p65.
Tat counteracts the IiB-a inhibition of p65 by
competing the repressor binding
We further investigated the physical interaction of Tat
with IkB-a using in vitro translated proteins in
coimmunoprecipitation assays. For mapping the inter-
action domains, we used the following Tat mutants: Tat
T,N(23,24)A, Tat C(22,25,27)A, Tat K(50,51)A and Tat
R(49–57)A (Figure 3A). IkB-a coimmunoprecipitated
with all Tat proteins, except Tat R(49–57)A (Figure 3B).
These results indicated that the arginine-rich domain of
Tat was involved in the binding to IkB-a, which was con-
sistent with previous observations (50,51). Moreover, Tat
associating with IkB-a competed the binding of IkB-a to
p65 in a dose-dependent manner (Figure 3C, lanes 3–5),
while Tat R(49–57)A, which lacked the binding site for
IkB-a, did not associate with IkB-a and did not compete
the binding of IkB-a to p65 (Figure 3C, lanes 6–8).
Next, we evaluated whether Tat counteracted the
IkB-a-mediated inhibition of p65 binding to DNA by
incubating in vitro translated p65 and IkB-a proteins with
the NF-kB probe in presence or absence of Tat followed by
Nucleic Acids Research,2012, Vol.40, No. 8 3551EMSA. The p65 DNA binding activity was inhibited by
IkB-a and restored in a dose-dependent manner by
wild-type Tat, and not by Tat R(49–57) (Figure 3D).
Further, we analysed the Tat effect on the IkB-a repression
of p65 transcriptional activity by transfecting p50
 / p65
 /
 MEFs withtheNF-kB-Luc reportertogetherwithexpres-
sion vectors of p65 and IkB-a, in presence or absence of
Tat. IkB-a inhibited the p65-dependent expression of the
luciferase gene, which was restored in a dose-dependent
manner by wild-type Tat, and not by Tat R(49–57)A
(Figure 3E). Altogether these results indicated that Tat
counteracts the IkB-a repression of the p65 DNA-
binding and transcriptional activity by associating with
IkB-a and competing the repressor binding to p65.
Figure 1. Tat counteracts the post-activation turn off of NF-kB in single round HIV-1-infection. Jurkat cells (5 10
7) were transfected with siRNA
Tat or siRNA control (2nmol), or left untransfected; 24h later, cells were infected with HXB2-pseudotyped NL4-3.Luc.R
 E
  virions (500ng of p24)
and harvested at the indicated time. (A) Tat expression was measured in total RNA by real-time PCR, while the luciferase activity was measured in
whole cell extracts. (B) Nuclear extracts (10mg) were analysed for the p65 and p50 binding to the NF-kB double-stranded oligonucleotide using the
NF-kB Transcription Factor ELISA Assay kit (Cayman). (C) The expression of p65 and IkB-a was analysed by 12% SDS–PAGE and western
blotting of nuclear or cytosolic extracts (20mg) using anti-p65 and anti-IkB-a antibodies. Histone H1 and Hexokinase II were detected with speciﬁc
antibodies as markers of nuclear and cytosolic extracts, respectively. Densitometry values (D) of the bands were expressed as fold increase above the
control (mock). (D) IKK activity was measured in cytosolic extracts (100mg) by using HTScan IKK Kinase Assay (Cell Signaling Technology).
Values (mean±SE, n=3) are shown.
3552 Nucleic Acids Research, 2012,Vol.40, No. 8Figure 2. Tat enhances the NF-kB activity following PMA stimulation by associating with IkB-a and counteracting the NF-kB repression. HeLa
cells (5 10
6) were transfected with p3xFLAG-Tat or p3xFLAG empty vector (5mg), and 48h later were stimulated with PMA (5min, 20ng/ml)
or left unstimulated, washed twice with DMEM and harvested at the indicated times. Nuclear and cytosolic extracts were prepared for further
analysis. (A) Nuclear extracts were analysed for the p65, p50 and FLAG-Tat binding to the NF-kB double-stranded oligonucleotide using the NF-kB
Transcription Factor ELISA assay kit (Cayman). (B) Nuclear and cytosolic extracts (20mg) were separated by 12% SDS–PAGE and analysed by
western blotting using the anti-p65, anti-FLAG, anti-Histone H1, anti-IkB-a and anti-Hexokinase-II antibodies. Densitometry values (D) of the
bands were expressed as fold increase above the control (lane 1). (C) IKK activity was measured in cytosolic extracts (100mg) by using HTScan IKK
kinase assay (Cell Signaling Technology). (D) HeLa cells (5 10
6) were transfected with or without p3xFLAG-Tat (5mg); 48h later, cells were
stimulated with PMA (5min, 20ng/ml) or left unstimulated, washed twice with DMEM, and harvested after 240min. Whole cell extracts (1mg) were
immunoprecipitated with protein G-Sepharose-coupled anti-IkB-a antibody. Immunocomplexes were separated by 12% SDS–PAGE and analysed by
western blotting with anti-p65, anti-FLAG and anti-IkB-a antibodies. Densitometry values (D) of the bands were expressed as fold increase above
the control (lane 1). Values (mean±SE, n=3) are shown.
Nucleic Acids Research,2012, Vol.40, No. 8 3553Tat increases the p65 afﬁnity binding to DNA through
association with p65
We tested whether Tat physically interacted with p65.
HeLa cells were transfected with the expression vectors
of HA-p65 and FLAG-Tat, and 24h later Tat was
immunoprecipitated from cell extracts. The p65 protein
was coimmunoprecipitated with wild-type Tat or the
mutants Tat T,N(23,24)A, Tat K(50,51)A and Tat
R(49–57)A at similar levels, while a signiﬁcant decrease
in coimmunoprecipitation was observed for Tat
C(22,25,27)A (Figure 4A). Consistently, GST-pull down
of in vitro translated proteins showed the direct binding of
p65 to wild-type Tat, or the mutants Tat T,N(23,24)A, Tat
K(50,51)A and Tat R(49–57)A, and lack of binding to
Figure 3. Tat relieves p65 from the IkB-a inhibition. (A) Schematic representation of wild-type and mutant Tat proteins. (B) HA-IkB-a (5ml) was
incubated in presence or absence of FLAG-Tat, FLAG-Tat T,N(23,24)A, FLAG-Tat K(50,51)A, FLAG-Tat R(49–57)A or FLAG-Tat C(22,25,27)A
(10ml) using in vitro translated proteins. Wild-type and mutant Tat proteins were immunoprecipitated with anti-FLAG antibody; immunocomplexes
were separated by 12% SDS–PAGE and analysed by western blotting with anti-HA and anti-FLAG antibodies. (C)
35S-methionine-labeled p65 (5ml)
was incubated with in vitro translated HA-IkB-a (5ml) in presence or absence of FLAG-Tat or FLAG-Tat R(49–57)A (5, 10 or 20ml). HA-IkB-a was
immunoprecipitated with anti-HA antibody; immunocomplexes were separated by 12% SDS–PAGE and analysed by western blotting with anti-HA
and anti-FLAG antibodies, or autoradiography (
35S-Met-p65). Densitometry values (D) of the bands were expressed as fold increase above the
control (lane 1). (D) The p65 DNA binding activity was analysed by EMSA using in vitro translated proteins.
32P-labeled-NF-kB double-stranded
oligonucleotide was incubated with p65 (0.5ml) in presence or absence of HA-IkB-a (1ml), FLAG-Tat or FLAG-Tat R(49–57)A (5 and 10ml);
competition of DNA binding was performed with 10- up to 100-fold molar excess of unlabeled NF-kB double-stranded oligonucleotide. DNA/
protein complexes were run on 6% PAGE–TBE and analysed by autoradiography. (E) p50
 / p65
 / MEFs (3 10
5 cells) were transfected with
pkBLuc (0.5mg) and pSV-b-Gal (0.1mg) with or without pRc/CMV-p65 (0.5mg), pCMV4-HA-IkB-a (0.5mg), p3xFLAG-Tat or p3xFLAG-Tat R(49–
57)A (0.5, 1 and 2mg). The luciferase activity was measured in cell extracts 48-h post-transfection and normalized to b-galactosidase activity. Fold
activation was calculated relative to transfection of the pkBLuc plasmid alone. Values (mean±SE, n=3) are shown. As control of protein
expression, aliquots of cell extracts (20mg) were analysed by western blotting with anti-p65, anti-HA, anti-FLAG and anti-g-tubulin antibodies.
3554 Nucleic Acids Research, 2012,Vol.40, No. 8Tat C(22,25,27)A (Figure 4B). These results indicated that
Tat associated with p65 through the cysteine-rich domain
and ruled-out the requirement of bridging proteins to
mediate such interaction.
To identify the p65 domain required for binding to
Tat, HeLa cells were transfected with FLAG-Tat
together with HA-p65 mutants, which were deleted
of the transactivation domain [p65C (1–318)], or the
RHD [p65N (122–551)] (Figure 4C). Tat coimmunopre-
cipitated with p65C (1–318), and not with
p65N (122–551) (Figure 4D), indicating that the RHD
of p65 was involved in the physical interaction with Tat.
Figure 4. Tat associates with p65 increasing its DNA-afﬁnity binding. (A) HeLa cells were transfected with pRc/CMV-3xHA-p65 (5mg) in presence
or absence of p3xFLAG-Tat, p3xFLAG-Tat T,N(23,24)A, p3xFLAG-Tat K(50,51)A, p3xFLAG-Tat R(49–57)A, or p3xFLAG-Tat C(22,25,27)A
(5mg). FLAG-Tat proteins were immunoprecipitated with anti-FLAG antibody; immunocomplexes were separated by 12% SDS–PAGE and
analysed by western blotting with anti-FLAG or anti-HA antibodies. (B) In vitro translated p65 (5ml) was incubated with GST-Tat, GST-Tat
T,N(23,24)A, GST-Tat K(50,51)A, GST-Tat R(49–57)A, GST-Tat C(22,25,27)A, or GST (5mg) conjugated with Glutathione-Sepharose. Protein
complexes were recovered by GST-pull down, separated by 12% SDS–PAGE, and analysed by western blotting with anti-p65 or anti-GST
antibodies. (C) Schematic representation of wild-type and mutant p65 proteins. (D) HeLa cells were transfected with p3xFLAG-Tat (5mg) in the
presence or absence of pRc/CMV-3xHA-p65, pRc/CMV-3xHA-p65C (1–318), or pRc/CMV-3xHA-p65N (122–551) (5mg). Wild-type and mutant
HA-p65 proteins were immunoprecipitated with anti-HA antibody; immunocomplexes were separated by 12% SDS–PAGE and analysed by western
blotting with anti-FLAG or anti-HA antibodies. (E) Recombinant p65 protein (100ng; Active Motif Carlsbad, CA, USA) was 20min incubated with
32P-labeled NF-kB double-stranded oligonucleotide in presence or absence of in vitro translated FLAG-Tat or FLAG-Tat C(22,25,27)A (5ml);
competitions were performed with 1.25- up to 40-fold molar excess of unlabeled oligonucleotide. DNA/protein complexes were separated by 6%
PAGE in 0.5 TBE buffer and analysed by autoradiography. (F) Densitometry of band-shifts shown in E.
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afﬁnity, puriﬁed recombinant p65 protein was incubated
with
32P-labeled-NF-kB double-stranded oligonucleotide
in presence or absence of wild-type Tat or Tat
C(22,25,27)A, and p65 DNA-binding was analysed by
EMSA. Whereas wild-type Tat signiﬁcantly increased
the binding of p65 to DNA, the mutant Tat
C(22,25,27)A, lacking the binding site for p65, was inef-
fective (Figure 4E). The p65 binding to DNA was
evaluated by competition with increasing amounts of
cold competitor NF-kB oligonucleotide, which showed
that Tat signiﬁcantly enhanced the p65 afﬁnity binding
to DNA (Figure 4E and F).
Tat activates the p65-dependent expression of NF-iB-
responsive genes, occupies the NF-iB enhancers and
promotes the p65 recruitment with IiB-a displacement
We analysed the action of Tat on the expression of
NF-kB-responsive genes in vivo. To this end, HeLa cells
were transfected with FLAG-Tat, FLAG-Tat
C(22,25,27)A or FLAG-Tat R(49–57)A, and 48h later
the expression of a number of NF-kB-dependent genes
was analysed by real-time PCR. Tat signiﬁcantly increased
the expression of MIP-1 , CSF3, LTA, NFKBIA
and TLR2, while the mutants Tat C(22,25,27)A and Tat
R(49–57)A were ineffective (Figure 5A–E). The
Tat-dependent transactivation of the NF-kB-dependent
genes was abolished when cells were transfected with
siRNA p65, indicating that the Tat transcriptional activa-
tion was mediated by p65 (Figure 5A–E). Differently, the
expression of the NF-kB-independent genes GAPDH and
ACTB was unaffected by wild-type and Tat mutants
(Figure 5F and G). These results were consistent with
the requirement of both the cysteine-rich and arginine-rich
domains of Tat to enhance the NF-kB activity, suggesting
that the up-regulation of NF-kB-responsive genes by Tat
might occur through physical interaction of the viral
protein with p65 and IkB-a.
MIP-1 , which was the mostly activated gene by Tat,
encodes for a chemokine that promotes the recruitment of
pro-inﬂammatory cells (56). Consistently with our
ﬁndings, MIP-1a expression was increased in glial cells
and lymph nodes of AIDS patients (57,58); moreover,
MIP-1a production was induced by HIV-1 infection
(59,60) and Tat protein (57,61,62). The transcriptional
regulation of MIP-1  has been poorly characterized.
Jaspar-based analysis (http://jaspar.genereg.net/) pre-
dicted three putative NF-kB enhancers in the proximal
promoter region of the MIP-1  gene: NF-kB1,  1023/
 1014 nucleotides; NF-kB2,  661/ 652 nucleotides;
NF-kB3, +370/+379 nucleotides (Supplementary Figure
S3A). To validate the predicted NF-kB binding sites of
the MIP-1  promoter, we stimulated HeLa cells with
TNF-a, a well-known NF-kB inducer, and measured the
expression levels of MIP-1  by real-time PCR, and the
p65 occupancy of the NF-kB sites by ChIP. TNF-a
activated the expression of MIP-1  and induced the p65
recruitment to the NF-kB1 site of MIP-1  without affect-
ing the occupancy of the putative NF-kB2 and NF-kB3
sites (Supplementary Figure S3B and S3C). Tat also
promoted the recruitment of p65 to the NF-kB1 site of
MIP-1 , while it did not affect the putative NF-kB2 and
NF-kB3 sites (Supplementary Figure S3D). Altogether
these results indicated that the NF-kB1 site was the only
effective NF-kB enhancer of the MIP-1  promoter in
response to TNF-a and Tat.
Similarly to MIP-1 , Tat increased the recruitment of
p65 to the NF-kB enhancers of CSF3, LTA, NFKBIA and
TLR2, while it was ineffective at the promoters of
GAPDH and ACTB (Figure 5H). By ChIP, Tat bound
to the NF-kB-responsive promoters, and not to the
GAPDH and ACTB promoters, with loss of binding fol-
lowing p65 RNA interference (Figure 5I), suggesting that
Tat occupancy occurred via p65 interaction. As additional
ﬁndings, IkB-a was chromatin-immunoprecipitated at the
NF-kB enhancers in absence of Tat, and it was signiﬁcant-
ly removed in presence of Tat, or following IkB-a RNA
interference (Figure 5J), indicating that Tat displaced
IkB-a from promoters.
In HIV-1-infected monocytes Tat sustains the NF-iB
activity and promotes the transcriptional activation of
MIP-1a by interacting with IiB-a and p65
We next analysed whether Tat affected the NF-kB activity
and the expression of MIP-1  in the course of HIV-1
infection. To detect the Tat protein, we produced HXB2
Env-pseudotyped NL4-3.FLAG-Tat.R
 E
  virions, which
were used in single-round infection of U937, a human
monocytic cell line. Cells were transfected with siRNA
Tat, siRNA control or left untransfected to modulate
the Tat expression, and then analysed for the kinetic of
NF-kB activation following viral infection. The expression
of Tat and p24 was detected at 3- to 12-h post-infection,
while it was barely detected in siRNA Tat-transfected cells
(Figure 6A).
The NF-kB activity, as measured by p65 DNA binding,
was induced at 3-h post-infection in both Tat-positive
(no siRNA and siRNA control) and Tat-negative
cells (siRNA Tat), and increased at 12h only in
Tat-positive cells (Figure 6B). Degradation of IkB-a was
observed at 3-h post-infection, and was followed by
de novo synthesis of IkB-a at 12h independently of the
Tat presence (Figure 6C). Consistently, the IKK
activity was induced at 3-h post-infection and turned off
at 12h independently of the Tat presence (Figure 6D).
These results agreed with the kinetic of NF-kB activation
in single-round HIV-1 infection of Jurkat cells (Figure 1),
and further supported the requirement of viral
expression to counteract the post-activation turn off of
NF-kB.
In HIV-1-infected U937 cells, the endogenous Tat was
coimmunoprecipitated with IkB-a and p65 (Figure 6E),
and activated the MIP-1  expression in a p65-dependent
manner, as shown by the lack of effect following RNA
interference of Tat or p65 (Figure 6F). Moreover, Tat
and p65 were both recruited to the NF-kB enhancer of
MIP-1 , while the p65 occupancy was abolished by
siRNA Tat (Figure 6G and H). Altogether these results
indicated that in single round HIV-1 infection Tat
associated with IkB-a and p65, and induced the
3556 Nucleic Acids Research, 2012,Vol.40, No. 8p65-dependent activation of MIP-1  expression through
occupancy of the MIP-1  promoter and increased recruit-
ment of p65.
DISCUSSION
This study reports a novel mechanism of NF-kB activa-
tion by the HIV-1 Tat transactivator. Based on the
evidence that Tat enhanced the transcriptional activity
of the p65 subunit of NF-kB (49,63,64), and physically
interacted with the IkB-a repressor (50,51), we
investigated the possibility that Tat could activate
NF-kB via direct interaction with IkB-a and p65. To
this end, the NF-kB activity was monitored in single
round HIV-1 infection using RNA interference to silence
the Tat expression. By this approach, we avoided the per-
petuation of NF-kB activation signaling due to
Figure 5. Tat activates the p65-dependent expression of NF-kB-responsive genes by occupying the NF-kB enhancers and promoting the p65
recruitment with IkB-a displacement. HeLa cells (5 10
6) were transfected with p3xFLAG-Tat, p3xFLAG-Tat C(22,25,27), p3xFLAG-Tat R(49–
57) or empty vector (10mg); for p65 RNA interference, cells (5 10
6) were transfected with p3xFLAG-Tat (10mg) and siRNA p65 or siRNA control
(200pmol). Twenty-four-hour post-transfection, total RNA was extracted and analysed by real-time PCR to evaluate the expression of MIP-1  (A),
CSF3 (B), LTA (C), NFKBIA (D), TLR2 (E), GAPDH (F), ACTB (G) genes. (H) HeLa cells (5 10
6) were transfected with p3xFLAG-Tat, or empty
vector (10mg) and 48h later ChIP was performed with anti-p65 antibody. Real-time PCR was performed with primers speciﬁc for the indicated
promoters. (I) HeLa cells (5 10
6) were transfected with empty vector, or p3xFLAG-Tat (10mg) in presence or absence of siRNA p65, or siRNA
control (200pmol); 48h later, ChIP was performed with anti-FLAG antibody. Real-time PCR was performed with primers speciﬁc for the indicated
promoters. (J) HeLa cells (5 10
6) were transfected with empty vector, p3xFLAG-Tat (10mg), or empty vector plus siRNA IkB-a or siRNA control
(200pmol); 48h later, ChIP was performed with anti-IkB-a antibody. Real-time PCR was performed with primers speciﬁc for the indicated pro-
moters. Values (mean±SE, n=3) are shown. The asterisks indicate statistically signiﬁcant differences compared to the control (empty vector)
according to the Student’s t-test (P<0.05).
Nucleic Acids Research,2012, Vol.40, No. 8 3557subsequent rounds of viral entry in cell culture propaga-
tion (30,31). Upon HIV-1 infection, the early NF-kB ac-
tivation occurred concomitantly with IKK activation and
IkB-a degradation in the absence of Tat. Soon after the
shut off of IKK activity and new synthesis of IkB-a, the
NF-kB activity was kept elevated in the presence of Tat,
while it was down regulated upon silencing of the Tat
gene. These ﬁndings indicate that in single round HIV-1
Figure 6. In HIV-1 infection Tat sustains the NF-kB activity and enhances the MIP-1  expression via interaction with IkB-a and p65. U937 cells
(5 10
7) were transfected with siRNA Tat, siRNA control (2nmol), or left untransfected; 24h later cells were infected with HXB2-pseudotyped
NL4-3.FLAG-Tat.R
 E
  virions (500ng of p24) and harvested at the indicated time. (A) Real-time PCR of total RNA measured the Tat expression;
ELISA measured the amount of p24 in whole cell extracts. (B) The binding of p65 to the NF-kB double-stranded oligonucleotide was measured in
nuclear extracts (10mg) using the NF-kB Transcription Factor ELISA assay kit (Cayman). (C) The IkB-a content was analysed by 12% SDS–PAGE
and western blotting of cytosolic extracts (20mg) using anti-IkB-a antibody. Densitometry values (D) of the bands were expressed as fold increase
above the control (mock). (D) IKK activity was measured in cytosolic cell extracts (100mg) using HTScan IKK Kinase Assay (Cell Signaling
Technology). (E) U937 cells (5 10
7) were infected with HXB2-pseudotyped NL4-3.FLAG-Tat.R
 E
  virions, or left uninfected. Twenty-four-hour
post-infection, cell extracts (1mg) were immunoprecipitated with protein G-Sepharose-coupled anti-FLAG antibody. Immunocomplexes were
separated by 12% SDS–PAGE and analysed by western blotting with anti-p65, anti-FLAG and anti-IkB-a antibodies. (F) U937 cells (5 10
7)
were transfected with siRNA Tat, siRNA p65, siRNA control (2nmol), or left untransfected; 24h later, cells were infected with HXB2-pseudotyped
NL4-3.FLAG-Tat.R
 E
  virions, or left uninfected. Twenty-four-hour post-infection, total RNA was analysed for MIP-1  expression by real-time
PCR. (G and H) U937 cells (5 10
7) were transfected with siRNA Tat or siRNA control (2nmol), or left untransfected; 24h later, cells were infected
with HXB2-pseudotyped NL4-3.FLAG-Tat.R
 E
  virions, or left uninfected. Twenty-four-hour post-infection, ChIP was performed with anti-p65
(G) or anti-FLAG (H). Real-time PCR was performed with primers speciﬁc for MIP-1  and GAPDH promoters. Values (mean±SE, n=3) are
shown. The asterisks indicate statistically signiﬁcant differences compared to the control (mock), according to the Student’s t-test (P<0.05).
3558 Nucleic Acids Research, 2012,Vol.40, No. 8infection, Tat enhanced the NF-kB activity without affect-
ing the IKK activity and the half-life of IkB-a. Similar
kinetic of NF-kB activation occurred upon short-pulse
of PMA in Tat-transfected HeLa cells, where Tat inhibited
the post-activation turn off of NF-kB in presence of newly
synthesized IkB-a.
The Tat-dependent activation of NF-kB correlated with
the association of the viral protein with IkB-a, which
interfered with the generation of the IkB-a/p65 complex.
This evidence demonstrated that Tat competed for the
binding of IkB-a to p65 and prevented the IkB-a repres-
sion of p65. As additional mechanism of NF-kB activa-
tion, Tat associated with p65 and increased the p65
binding afﬁnity to the NF-kB enhancer; this evidence
was obtained with recombinant proteins indicating that
the stronger binding of p65 to DNA was a consequence
of direct association with Tat, which likely caused a
conformational change of p65. We also demonstrated
that the Tat cysteine-rich sequence (C22,25,27) was
involved in the binding to the RHD of p65 and NF-kB
activation. Differently, the Tat arginine-rich sequence
(R49,52,53,55,56,57) was required for the binding to the
sixth ankyrin of IkB-a (50,51), and for releasing p65 from
the IkB-a inhibition. Altogether these results demo-
nstrated that Tat abolished the negative feedback regula-
tion of NF-kB by hijacking the IkB-a repressor, shielding
p65 from the IkB-a embrace, and enforcing the p65
binding to DNA.
Further evidence of Tat activation of NF-kB showed
that wild-type Tat, and not the Tat mutants lacking the
arginine- or cysteine-rich domains, up-regulated in vivo
the expression of a number of NF-kB-responsive genes,
including MIP-1 , CSF3, LTA, NFKBIA and TLR2.
By ChIP analysis, we observed that Tat increased the re-
cruitment of p65 to the NF-kB enhancers of the activated
genes, and was recovered at the same sites. RNA interfer-
ence of p65 abolished the Tat occupancy of the NF-kB
enhancers indicating that the Tat binding to the NF-kB
sites was mediated by p65. These results were consistent
with the evidence that Tat displaced p65 from the binding
to IkB-a (Figures 2D and 3C), and increased the p65 DNA
binding afﬁnity through association (Figure 4E and F).
Thus, Tat likely increased the recruitment of p65 to the
NF-kB-dependent promoters by associating with p65 and
by interfering with the assembly of p65 with the repressor
IkB-a.
Of interest, IkB-a was found associated to the NF-kB
enhancers in absence of Tat, where it was displaced in
presence of Tat. These results suggest a negative regula-
tory role of IkB-a in gene regulation through occupancy
of speciﬁc promoters. Indeed, IkB-a was found associated
with hystone deacetylases at the hes1 promoter, from
where it was removed following TNF-a stimulation
causing histone acetylation and hes1 transcriptional acti-
vation (65). A similar mechanism of gene regulation could
apply to the NF-kB-dependent genes analysed in this
study, where Tat could activate the gene expression by
removing IkB-a and promoting the p65 loading
(Figure 7).
The physiological relevance of Tat cross talk with
NF-kB was demonstrated in the HIV-1 infection of
human monocytes, where HIV-1-encoded Tat protein
counteracted post-activation turn off of NF-kB, as
shown by: (i) sustained NF-kB activity by Tat in
presence of newly synthesized IkB-a; (ii) coimmunopre-
cipitation of Tat with IkB-a and p65; (iii) induction of
Figure 7. Model of MIP-1  transcriptional activation by HIV-1 Tat. (A) In absence of Tat, IkB-a occupies the NF-kB enhancer of the MIP-1 
promoter and likely interacts with transcriptional repressors, such as HDACs (65), to inhibit gene transcription. (B) Tat activates the MIP-1 
expression by removing the IkB-a repressor from the NF-kB enhancer, and by increasing the binding of p65 NF-kB complex to the NF-kB enhancer.
Nucleic Acids Research,2012, Vol.40, No. 8 3559MIP-1  expression dependent on Tat and p65; (iv) Tat
occupancy of the MIP-1  NF-kB enhancer associated
with increased recruitment of p65.
This study supports the pro-inﬂammatory action of Tat
through physical interaction with p65 and IkB-a. Several
inﬂammatory cytokines under the transcriptional control
of NF-kB are hyper-expressed in HIV-1 infected individ-
uals, including IL-6 (66,67), TNF-  (68), and MIP-1  (57–
62,69–71). In the case of TNF-  and IL-6, Tat activated
the cytokine expression by binding to the TAR-like stem
loop of the 50 transcript, thus likely promoting the tran-
scriptional elongation (33,37,47). Here, we have shown
that the Tat-dependent transcriptional activation of a
number of pro-inﬂammatory genes required the
assembly of Tat with p65 at the NF-kB enhancer
together with the displacement of IkB-a (Figure 5).
Thus, in the set of distinct NF-kB-responsive genes, Tat
acted as a component of the transcriptional initiation
complex, which is consistent with previous reports on
Tat promoting the transcription via DNA motifs (72,73).
Overproduction of pro-inﬂammatory cytokines is con-
sidered a major mechanism of immune deregulation (26)
and neuron dysfunction in AIDS (74,75). In this scenario,
inhibition of NF-kB activity could lead to a therapeutic
strategy for counteracting the abnormal production of
pro-inﬂammatory cytokines and chemokines in HIV-1 in-
fection. NF-kB inhibitors, such as anti-oxidants, prote-
asome and IKK inhibitors, signiﬁcantly reduced the
HIV-1 replication and the associated inﬂammatory
response (76,77); however, these NF-kB inhibitors acted
indiscriminately in both HIV-1-infected and uninfected
cells. The evidence that Tat activates NF-kB through
direct interaction with IkB-a and p65 may lead to
speciﬁc inhibitors to counteract the Tat pro-inﬂammatory
action.
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